.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,370,509

« Back to Dashboard

Details for Patent: 9,370,509

Title:2.times.2.times.2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod
Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara.RTM. 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara.RTM. 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
Inventor(s): Nordsiek; Michael T. (Berwyn, PA), Levy; Sharon F. (Philadelphia, PA), Lee; James H. (Devon, PA), Kulp; James H. (West Chester, PA), Balaji; Kodumudi S. (Downingtown, PA), Meng; Tze-Chiang (Lino Lakes, MN), Wu; Jason J. (Wayne, PA), Bahm; Valyn S. (Phoenixville, PA), Babilon; Robert (Boyertown, PA)
Assignee: Medicis Pharmaceutical Corporation (Bridgewater, NJ)
Filing Date:Aug 06, 2012
Application Number:13/568,003
Claims:1. A method for treating actinic keratosis (AK) in an immunocompetent adult in need thereof, comprising: (a) topically applying once daily a 2.5% (w/w) imiquimod composition to the full face or balding scalp of the patient for a first two-week treatment period, wherein the topically applied imiquimod composition is applied to said full face or balding scalp and rubbed in until no longer visible, left on said full face or balding scalp for about eight hours and then removed from said full face or balding scalp by washing; and (b) topically applying once daily a 2.5% (w/w) imiquimod composition to the full face or balding scalp of the patient for a second two-week treatment period, wherein the topically applied imiquimod composition is applied and rubbed in until no longer visible, left on said full face or balding scalp for about eight hours and then removed from said full face or balding scalp by washing; wherein the first treatment period and the second treatment period are separated by one, two-week non-treatment period during which no imiquimod is applied; wherein said method of treating actinic keratoses is completed in six weeks; and wherein in performance of the method, the imiquimod is the sole active pharmaceutical ingredient required to be applied to the full face or balding scalp.

2. The method of claim 1, wherein 250-500 mg of the imiquimod composition is applied.

3. The method of claim 1, wherein at least 6.25 mg to 12.5 mg of imiquimod is applied daily during the two-week treatment periods.

4. The method of claim 1, wherein at least 43.75 mg to 87.5 mg of imiquimod is applied weekly during the two-week treatment periods.

5. The method of claim 1, wherein at least 87.5 mg to 175 mg of imiquimod is applied during the two-week treatment periods.

6. The method of claim 1, wherein at least 175 mg to 350 mg of imiquimod is applied on a 6-week treatment course.

7. The method of claim 1, wherein performance of the method results in complete clearance of the actinic keratoses in the full face or scalp of the immunocompetent adult.

8. The method of claim 7, wherein performance of the method in a population of immunocompetent adults in need thereof results in a statistically significant improvement in the percent of total clearance of actinic keratoses compared to treatment with placebo.

9. The method of claim 8, wherein performance of the method in the population of immunocompetent adults in need thereof results in about 25% or greater complete clearance of actinic keratoses in the immunocompetent adults in the population.

10. The method of claim 1, wherein the AK is clinically typical, visible or palpable.

11. The method of claim 1, wherein applying the 2.5% imiquimod composition continues in each one of the two-week treatment periods even if no actinic keratoses are visible.

12. The method of claim 1, wherein the 2.5% imiquimod composition is applied to the full face.

13. The method of claim 1, wherein the 2.5% imiquimod composition is applied to the balding scalp.

14. The method of claim 1, wherein the full face is at least 200-250 cm.sup.2.

15. The method of claim 1, wherein performance of the method results in the clearance of at least 75% of the actinic keratoses in the full face or scalp of the immunocompetent adult.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc